In a report published Tuesday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating on Actavis plc ACT, and raised the price target from $246.00 to 254.00.
In the report, Bank of America noted, “We like ACT's business mix (brands/generics/biosimilars), geographic footprint, thoughtful and targeted R&D strategy, strong management team, and business development approach. We believe the acquisitions of Warner and FRX put Irish-domiciled ACT in a strong strategic and financial position for an evolving Pharma landscape in the years ahead.”
Actavis plc closed on Monday at $214.94.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in